Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials

This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two comp...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 11; p. 3251
Main Authors Le-Rademacher, Jennifer G., Hillman, Shauna, Storrick, Elizabeth, Mahoney, Michelle R., Thall, Peter F., Jatoi, Aminah, Mandrekar, Sumithra J.
Format Journal Article
LanguageEnglish
Published MDPI AG 04.11.2020
MDPI
Subjects
Online AccessGet full text
ISSN2072-6694
2072-6694
DOI10.3390/cancers12113251

Cover

Abstract This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials’ primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles.
AbstractList This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials' primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles.This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials' primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles.
In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which includes 837 terms. The vast number of potentially reportable adverse events over multiple treatment cycles makes summarizing and analyzing adverse event data challenging. The current standard reporting of adverse event data includes the frequency of the maximum (worst) grade of commonly occurring adverse events. In this article, we propose a single quantitative summary measure that incorporates both the frequency and the severity of multiple adverse events over time; the adverse event burden score. This score is a well-defined measure that enables statistical comparisons analogous to other quantitative endpoints in clinical trials. The adverse event burden score can readily accommodate different trial settings, diseases, and treatments, with diverse safety profiles.
This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials’ primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles.
Audience Academic
Author Jatoi, Aminah
Storrick, Elizabeth
Le-Rademacher, Jennifer G.
Thall, Peter F.
Mandrekar, Sumithra J.
Hillman, Shauna
Mahoney, Michelle R.
AuthorAffiliation 2 IQVIA, Raleigh-Durham, NC 27703, USA; mahoney.michelle@mayo.edu
1 Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; hillman.shauna@mayo.edu (S.H.); storrick.elizabeth@mayo.edu (E.S.); mandrekar.sumithra@mayo.edu (S.J.M.)
4 Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA; jatoi.aminah@mayo.edu
3 Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX 77230, USA; rex@mdanderson.org
AuthorAffiliation_xml – name: 4 Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA; jatoi.aminah@mayo.edu
– name: 1 Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; hillman.shauna@mayo.edu (S.H.); storrick.elizabeth@mayo.edu (E.S.); mandrekar.sumithra@mayo.edu (S.J.M.)
– name: 3 Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX 77230, USA; rex@mdanderson.org
– name: 2 IQVIA, Raleigh-Durham, NC 27703, USA; mahoney.michelle@mayo.edu
Author_xml – sequence: 1
  givenname: Jennifer G.
  orcidid: 0000-0002-2234-7430
  surname: Le-Rademacher
  fullname: Le-Rademacher, Jennifer G.
– sequence: 2
  givenname: Shauna
  surname: Hillman
  fullname: Hillman, Shauna
– sequence: 3
  givenname: Elizabeth
  surname: Storrick
  fullname: Storrick, Elizabeth
– sequence: 4
  givenname: Michelle R.
  surname: Mahoney
  fullname: Mahoney, Michelle R.
– sequence: 5
  givenname: Peter F.
  surname: Thall
  fullname: Thall, Peter F.
– sequence: 6
  givenname: Aminah
  surname: Jatoi
  fullname: Jatoi, Aminah
– sequence: 7
  givenname: Sumithra J.
  surname: Mandrekar
  fullname: Mandrekar, Sumithra J.
BookMark eNp1UctOHDEQtBAR7zNXS1xyWfBjbM9cIm1WG0AC5bCEq-Xx9IAjrw32zErc-Ih8IV-Cl0VRQEpfutVdVaru3kfbIQZA6JiSU84bcmZNsJAyZZRyJugW2mNEsYmUTbX9T72LjnL-TUpwTpVUO2i3FKImNdlDi2m3KhqA5ysIA_4-pg4CXtiY4OX5zxTflqEZnAe8GJdLk57wNZg8JsB9THj25gDPvAvOGo9vkjM-H6IvfUlw9J4P0K8f85vZxeTq5_nlbHo1sZWshonsmqrmBpq2la1VgkkOPVcgut4YRU3TM1m6gkGrmhZqwlVdt7SRvGwlQPED9G2j-zC2S-hsWSAZrx-SWxvV0Tj9cRLcvb6LK63KVRitisDXd4EUH0fIg166bMF7EyCOWbNK1IqpSjUFerKB3hkP2oU-FkW7huuprARhXHJSUGcblE0x5wT9XzOU6PXP9KefFYb4xLBuKAePa8fO_5f3CvfOnag
CitedBy_id crossref_primary_10_1080_10543406_2025_2456176
crossref_primary_10_3389_fonc_2023_1211544
crossref_primary_10_1016_j_clinthera_2023_10_007
crossref_primary_10_1016_j_ijrobp_2021_11_024
crossref_primary_10_1080_19466315_2023_2166099
crossref_primary_10_1200_JCO_24_00979
crossref_primary_10_1186_s12874_021_01368_w
crossref_primary_10_1111_rssc_12582
crossref_primary_10_3390_cancers17061039
crossref_primary_10_1016_S2352_3026_22_00045_X
crossref_primary_10_1038_s41375_021_01342_x
crossref_primary_10_1080_1120009X_2024_2302736
crossref_primary_10_1136_bmjopen_2021_053456
crossref_primary_10_3390_cancers15041344
crossref_primary_10_3390_jcm11206178
crossref_primary_10_1136_jitc_2022_005493
crossref_primary_10_1182_blood_2022018818
crossref_primary_10_1007_s00270_023_03391_4
crossref_primary_10_1016_S2352_3026_22_00226_5
crossref_primary_10_4049_jimmunol_2300185
crossref_primary_10_3390_cancers13112741
Cites_doi 10.1198/016214504000000043
10.1111/rssc.12117
10.1016/j.ctrv.2019.04.004
10.1093/annonc/mdx043
10.2147/CMAR.S166468
10.1016/S2352-3026(20)30067-3
10.1016/S1470-2045(16)00038-3
10.1002/cncr.29544
10.1016/j.lungcan.2007.10.003
10.1200/JCO.2009.27.4282
10.1056/NEJMoa1805052
ContentType Journal Article
Copyright COPYRIGHT 2020 MDPI AG
2020 by the authors. 2020
Copyright_xml – notice: COPYRIGHT 2020 MDPI AG
– notice: 2020 by the authors. 2020
DBID AAYXX
CITATION
7X8
5PM
DOI 10.3390/cancers12113251
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC7694214
A645023630
10_3390_cancers12113251
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
7X8
PQGLB
PUEGO
5PM
ID FETCH-LOGICAL-c464t-6d9483ae9bb6bc75263ef37e5dfaa71a9f2675252eb79be803788b19636695e73
IEDL.DBID M48
ISSN 2072-6694
IngestDate Thu Aug 21 18:21:25 EDT 2025
Fri Sep 05 06:19:57 EDT 2025
Tue Jun 17 21:35:03 EDT 2025
Tue Jul 01 01:52:06 EDT 2025
Thu Apr 24 23:09:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-6d9483ae9bb6bc75263ef37e5dfaa71a9f2675252eb79be803788b19636695e73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2234-7430
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers12113251
PMID 33158080
PQID 2458727479
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7694214
proquest_miscellaneous_2458727479
gale_infotracmisc_A645023630
crossref_primary_10_3390_cancers12113251
crossref_citationtrail_10_3390_cancers12113251
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20201104
PublicationDateYYYYMMDD 2020-11-04
PublicationDate_xml – month: 11
  year: 2020
  text: 20201104
  day: 4
PublicationDecade 2020
PublicationTitle Cancers
PublicationYear 2020
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Gounder (ref_8) 2018; 379
George (ref_13) 2019; 76
Johnson (ref_7) 2008; 60
Schuurhuizen (ref_6) 2018; 10
Tseng (ref_4) 2015; 121
Bekele (ref_3) 2004; 99
Thanarajasingam (ref_10) 2020; 7
ref_1
Hobbs (ref_5) 2016; 65
Hillman (ref_11) 2010; 28
Hillman (ref_12) 2017; 28
ref_2
Thanarajasingam (ref_9) 2016; 17
References_xml – volume: 99
  start-page: 26
  year: 2004
  ident: ref_3
  article-title: Dose-finding based on multiple toxicities in a soft tissue sarcoma trial
  publication-title: J. Am. Stat. Assoc.
  doi: 10.1198/016214504000000043
– volume: 65
  start-page: 273
  year: 2016
  ident: ref_5
  article-title: Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival
  publication-title: J. R. Stat. Soc. Ser. C
  doi: 10.1111/rssc.12117
– ident: ref_2
– volume: 76
  start-page: 33
  year: 2019
  ident: ref_13
  article-title: Improving attribution of adverse events in oncology clinical trial
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2019.04.004
– volume: 28
  start-page: 1183
  year: 2017
  ident: ref_12
  article-title: Value of adverse events relatedness to study treatment: Analyses of data from randomized double-blind placebo-controlled clinical trials
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx043
– volume: 10
  start-page: 3015
  year: 2018
  ident: ref_6
  article-title: The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S166468
– volume: 7
  start-page: e490
  year: 2020
  ident: ref_10
  article-title: Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: A case study of lenalidomide in the CALGB 50401 (Alliance) trial
  publication-title: Lancet Haematol.
  doi: 10.1016/S2352-3026(20)30067-3
– volume: 17
  start-page: 663
  year: 2016
  ident: ref_9
  article-title: Longitudinal adverse event assessment in oncology clinical trials: The Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(16)00038-3
– volume: 121
  start-page: 3659
  year: 2015
  ident: ref_4
  article-title: Phase I adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high risk extremity and trunk soft tissue sarcoma
  publication-title: Cancer
  doi: 10.1002/cncr.29544
– volume: 60
  start-page: 200
  year: 2008
  ident: ref_7
  article-title: Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2007.10.003
– ident: ref_1
– volume: 28
  start-page: 3002
  year: 2010
  ident: ref_11
  article-title: Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2009.27.4282
– volume: 379
  start-page: 2417
  year: 2018
  ident: ref_8
  article-title: Sorafenib for Advanced and Refractory Desmoid Tumors
  publication-title: N. Engl J. Med.
  doi: 10.1056/NEJMoa1805052
SSID ssj0000331767
Score 2.354484
Snippet This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient...
In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which...
SourceID pubmedcentral
proquest
gale
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 3251
SubjectTerms Cancer
Care and treatment
Clinical trials
Methods
Title Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials
URI https://www.proquest.com/docview/2458727479
https://pubmed.ncbi.nlm.nih.gov/PMC7694214
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB5RkBAXRGmrhke0SBx6MY336T0glKIAQgqqGiLlZnnXa1EpMiUJEtz4EfxCfgkztnlF9MJ5d21rHjvzrWe_AdjlQqHXuDzKvUSAIooiSqR1kbQYLPJOxoWvCmTP9MlQno7U6KUdUCPA6bvQjvpJDSfjvZur2wN0-H1CnAjZf3qSz2RKZGWC03XqJQxLnEy83-T61bYsMFRqU9P7vLduBZZxikoqishXQWp-q54vn3wVj47WYLVJJFm31vxnWAjlOiz3m1_lX2BQtVqeBtajikZWX1dgA2KtfLi77zI6KEOtjAMb1PfXWL8-LmSYxrLD6qNZwxo6ZueVnX6F4VHv_PAkajooRF5qOYt0bmUismCd084bxbUIhTBB5UWWmTizBUfAwBUPzlgXkg6xyztySq2tCkZ8g8XysgzfgcW6QHSmvSwyJ7XLrfcBkx-rCszJRJy3YO9JZKlv6MWpy8U4RZhB4k7nxN2CH88L_tXMGv-fukU6SMkK8JkePcCnXS0V0d-LTgt2nnST0hCVjZXh8nqacqkSQ7jbtsC8UdrzK4le--1I-feiotk22koey40Pr9yEFU7onA6h5RYszibXYRtTmJlrw9Kv3tnvP234dDyK25WhPgK4XvYk
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adverse+Event+Burden+Score%E2%80%94A+Versatile+Summary+Measure+for+Cancer+Clinical+Trials&rft.jtitle=Cancers&rft.au=Le-Rademacher%2C+Jennifer+G.&rft.au=Hillman%2C+Shauna&rft.au=Storrick%2C+Elizabeth&rft.au=Mahoney%2C+Michelle+R.&rft.date=2020-11-04&rft.pub=MDPI&rft.eissn=2072-6694&rft.volume=12&rft.issue=11&rft_id=info:doi/10.3390%2Fcancers12113251&rft_id=info%3Apmid%2F33158080&rft.externalDocID=PMC7694214
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon